Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease

Clinical Nephrology

Volumn 51, Issue 2, 1999, Pages 108-115

  Dierkes, J ^a,b   Domrose U ^a   Ambrosch, A ^a   Bosselmann, H P ^a   Neumann, K H ^a   Luley, C ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Institute of Clinical Chemistry   (Germany)

Author keywords

Folic acid; Hemodialysis; Homocysteine

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; DIET SUPPLEMENTATION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PERITONEAL DIALYSIS;

ADULT; ERYTHROCYTES; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 0344699328     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Arnadottir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P 1993 The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephol 40: 236-240
2. Arnadottir M, Hultberg B, Andersson A, Nilsson-Ehle P, Thysell H 1996 The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56: 41-46
3. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W 1995 Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6: 121-125
4. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J 1995 Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116: 59-62
5. Bostom AG, Shernin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg JH 1996 High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49: 147-152
6. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg JH 1996 Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123: 193-202
7. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH 1997 Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17: 2554-2558
8. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL 1988 Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48: 215-221
9. Butterworth CE, Tamura T 1989 Folic acid safety and toxicity: a brief review. Am J Clin Nutr 50: 353-358
10. Chaveau P, Chadefaux B, Coude M, Aupetit J, Kamoun P, Jungers P 1992 Long term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Elctrolyte Metab 22: 106-109
11. Chaveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Jungers P 1993 Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43 (Suppl 41): S72-S77
12. Descombes E, Hanck AB, Fellay G 1993 Water soluble vitamies in chronic hemodialysis patients and need for supplementation. Kidney Int 43: 1319-1328
13. van Guldener C, Janssen MJFM, Lambert J, ter Wee PM, Jakobs C, Donker AJM, Stehouwer CDA 1998 No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in haemodialysis patients. Nephrol Dial Transplant 13: 106-112
14. Guttormsen AB, Ueland PM, Svarstad E, Refsum H 1997 Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 52: 495-502
15. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schmid R, Hörl WH, Sunder-Plassmann G 1997 Mutation in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52: 517-523
16. Hultberg B, Andersson A, Stemer G 1993 Plasmahomocysteine in renal failure. Clin Nephron 40: 230-234
17. Hultberg B, Andersson A, Arnadottir M 1995 Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron 70: 62-67
18. Janssen MJFM, van Guldener C, de Jong GMT, van den Berg M, Stehouwer CDA, Donker AJM 1996 Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Elctrolyte Metab 22: 110-114
19. Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH 1993 Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 58: 468-476
20. Kjellstrand CM, Hylander B, Collins AC 1990 Mortality on dialysis- on the influence of early start, patient characteristics and transplantation and acceptance ratest. Am J Kid Dis 15: 483-490
21. Khuijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oust BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ 1996 Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58: 35-41
22. Khuijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JW, van den Heuvel LPWJ, Trijbels FJM, Boerma GJM, Verheugt FWA, Willems F, Blom HJ 1997 Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 96: 2573-2577
23. Ma KW, Greene EL, Raij L 1992 Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kid Dis 19: 505-513
24. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW 1997 Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138-141
25. 6 and ist requirement in chronic renal failure. Kidney Int 62 (Suppl): S56-S59
26. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW 1996 Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94: 2743-2748
27. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J 1988 Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 81: 466-474
28. Ubbink JB, Vermaak WJ, van der Merve A, Becker PJ, Delport R, Potgieter HC 1994 Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124: 1927-1933
29. Vester B, Rasmussen K 1991 High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 29: 549-554
30. Westhuyzen J, Matherson K, Tracey R, Fleming SJ 1993 Effect of withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 410: 96-99
31. Wilcken DEL, Dudman NPB, Tyrell RA, Robertson MR 1988 Folic acid lowers elevated plasma homocysteine levels in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 37: 697-701